Latest Pharma and Biotech News
Pharmaceutical
9 January 2025 Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare.
Today's issue
Refine Search
Pharmaceutical
USA-based Light Horse Therapeutics has been established as a new small molecule therapeutics developer, with a $62 million Series A financing led by founding investor Versant Ventures and partnered with Novartis to identify and develop potentially advanced therapeutics. 10 January 2025
Pharmaceutical
The glaucoma market across the seven major markets is forecast to increase at a compound annual growth rate (CAGR) of 2.1% from $2.1 billion in 2023 to $2.5 billion in 2033. 10 January 2025
Pharmaceutical
German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as non-hormonal treatment for moderate to severe vasomotor symptoms caused by adjuvant endocrine therapy in women with hormone receptor positive breast cancer or in women at high risk of developing breast cancer. 9 January 2025
Pharmaceutical
Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to redefine the future of healthcare. 9 January 2025
Pharmaceutical
UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on developing innovative therapies for obesity and other cardiometabolic disorders. 9 January 2025
Pharmaceutical
Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and peripheral nervous system, has announced a deal with South Korea’s Myung In Pharm. 9 January 2025
Pharmaceutical
British pharma major AstraZeneca has received positive news from the reimbursement from the UK’s health technology assessor. 9 January 2025
Pharmaceutical
German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief scientific officer (CSO) and a member of the corporate executive board, effective February 1, 2025. 9 January 2025
Pharmaceutical
Insilico Medicine, a biotechnology firm specializing in artificial intelligence-powered drug discovery, has raised over $100 million in a series E funding round. 8 January 2025
Pharmaceutical
Calico Life Sciences, a biotech founded by Alphabet and Arthur Levinson focused on the biology of aging and age-related diseases, has announced a setback. 8 January 2025
Pharmaceutical
Denmark’s Novo Nordisk and Valo Health today announced they have entered into an expanded agreement to discover and develop novel treatments for obesity, type 2 diabetes, and cardiovascular disease based on Valo’s extensive human dataset and computation powered by artificial intelligence (AI). 8 January 2025
Pharmaceutical
Antag Therapeutics, a Denmark-based biopharma developing novel treatments for obesity, has announced the appointment of Joerg Moeller as chief executive officer, effective immediately. 8 January 2025
Pharmaceutical
The US Food and Drug Administration has imposed a label change for two new respiratory syncytial virus (RSV) vaccine rivals. 8 January 2025
Pharmaceutical
Metsera today announced positive data from a 12-week Phase IIa clinical trial of MET-097i, its potential once-monthly, ultra-long acting, subcutaneously injectable, fully-biased, GLP-1 receptor agonist (RA). 7 January 2025
Pharmaceutical
Central nervous system (CNS) specialist Neuraxpharm Group has acquired Provigil (modafinil) and Nuvigil (armodafinil), both of which are indicated for the treatment of excessive daytime sleepiness (EDS) in adults with narcolepsy. 7 January 2025
Pharmaceutical
Japan-based FUSO Pharmaceutical Industries and Australia’s Dimerix Limited have entered into an exclusive development and license agreement for the development and commercialization of Dimerix’ Phase III drug candidate DMX-200 for the treatment of focal segmental glomerulosclerosis (FSGS) kidney disease in Japan. 7 January 2025
Pharmaceutical
The heart failure market is projected to grow at a compound annual growth rate of 9.6% over the next decade, increasing from $13.5 billion in 2022 to $33.7 billion in 2032 across seven major markets, according to a report from analytics firm GlobalData. 7 January 2025
Pharmaceutical
A late-stage trial failure has dented Denali Therapeutics stock, with an announcement Monday revealing the HEALEY ALS study missed all endpoints. 7 January 2025
Pharmaceutical
Unquestionably, US drugmaker Vertex Pharmaceuticals is the dominant drug developer in the cystic fibrosis (CF) space.
How has the company achieved this — on the R&D and patient access side — and what is the company doing to help the remaining patients? Vertex’s Andrew Wilfin, Senior Country Medical Director, UK and Ireland, took part in a Q&A with The Pharma Letter to reveal all. 7 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) issued a draft guidance to provide recommendations on the use of artificial intelligence (AI) intended to support a regulatory decision about a drug or biological product’s safety, effectiveness or quality. 7 January 2025
All news
Pharmaceutical
Israel and USA-based artificial intelligence (AI) company Quris-AI says that it has agreed to expand its existing partnership with Germany’s Merck KGaA. 29 September 2023
Pharmaceutical
US financial services company Morningstar has published its Biopharma Pipeline Report which provides a five-year outlook on key trends in the space, as well as an in-depth review of pipelines and major therapeutic areas. 29 September 2023
Pharmaceutical
The UK pharma industry has responded to proposed changes to the statutory scheme for branded medicines, arguing against their implementation. 29 September 2023
Pharmaceutical
Karuna Therapeutics has taken a significant step with its submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for KarXT (xanomeline-trospium), its ground-breaking product aiming to revolutionize the treatment of schizophrenia. 28 September 2023
Pharmaceutical
Ophthalmic company Ocuphire Pharma, a specialist in retinal and refractive eye disorders, together with partner Viatris, have secured US approval for Ryzumvi (phentolamine). 27 September 2023
Pharmaceutical
US biopharma Soleno Therapeutics saw its market capitalization leap five-fold yesterday, with the shares hitting $26.80, after it announced promising research results for its lead pipeline candidate, which has encountered previous setbacks. 27 September 2023
Pharmaceutical
USA-based Ionis Pharmaceuticals yesterday released positive top-line results for the Phase III Balance study of olezarsen in people with familial chylomicronemia syndrome (FCS), a rare genetic disorder. 27 September 2023
Pharmaceutical
Molnupiravir, an antiviral treatment for COVID-19 marketed by US pharma giant Merck & Co under the name Lagevrio, could in fact lead to the virus mutating, according to a research article. 26 September 2023
Pharmaceutical
A $250 million private financing for California’s BridgeBio Pharma will support a possible launch of acoramidis, as well as further late-stage pipeline development. 26 September 2023
Pharmaceutical
Australian dermatology company Botanix today revealed it has received a communication from the US Food and Drug Administration (FDA) in relation to its New Drug Application (NDA) submission for sofpironium bromide (SB) gel, 15%. 26 September 2023
Pharmaceutical
Danish company Acesion Pharma has closed an oversubscribed Series B financing round, raising around 43 million euros ($48 million) to support its work in atrial fibrillation (AF). 26 September 2023
Pharmaceutical
Senior vice president and head of research at GSK), John Lepore, has left the UK pharma major. 25 September 2023
Pharmaceutical
Danish drugmaker Novo Nordisk and Valo Health have entered into an agreement to discover and develop novel treatments for cardiometabolic diseases. 25 September 2023
Pharmaceutical
Research is repeatedly showing that co-administration of individual drugs as combination therapy offers significant benefits to patients. 25 September 2023
Pharmaceutical
Continuing its recent strong investment in the area of oncology, French privately-held company Pierre Fabre has inked a new drug discovery deal with British firm Vernalis. 25 September 2023
Pharmaceutical
Privately-held Danish company MC2 Therapeutics has acquired option rights from US dermatology firm Regranion to exclusively license the latter’s RGRN-305 for the treatment of all human diseases. 25 September 2023
Pharmaceutical
Swiss pharma major Novartis has announced the Phase III NETTER-2 trial of Lutathera (lutetium Lu 177 dotatate) has met its primary endpoint. 25 September 2023
Pharmaceutical
Plans to overhaul the European Union (EU) regulation on rare disease therapies risk undermining two decades of progress, a new report has found. 25 September 2023
Pharmaceutical
As part of the regular updates of the Association of Pharmaceutical Companies of Greece (SFEE) with representatives of the Patient Associations, another meeting of the SFEE Patient Think Tank was held this month. 25 September 2023
Pharmaceutical
Adding to a list of indications for the blockbuster drug, the US Food and Drug Administration (FDA) on Friday approved Jardiance (empagliflozin) 10mg tablets to reduce the risk of sustained decline in estimated glomerular filtration rate (eGFR), end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease (CKD) at risk of progression. 23 September 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze